Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

AFT Pharmaceuticals considering an IPO

AFT Pharmaceuticals considering an IPO to accelerate international growth
\
Growing New Zealand and Australia based multinational pharmaceutical company, AFT Pharmaceuticals, has announced today that it is considering an initial public offering and listing on the NZX Main Board and ASX.

Dr Hartley Atkinson and his wife Marree founded AFT Pharmaceuticals in their garage in 1997 with startup capital of only NZ$50,000. AFT now markets more than 100 products over a wide range of therapeutic categories and annual operating revenues have grown at a compound annual growth rate of 21% over the last 10 years.

AFT’s products are sold to a large majority of hospitals and nearly all pharmacies in New Zealand and Australia. In New Zealand, its products such as Maxigesic can be found in all major supermarket chains.

CEO of AFT Pharmaceuticals, Hartley Atkinson, says the time is right for the company to consider an IPO and raise capital as it embarks on its next phase of global growth.

“We believe that our business is set up to perform well on the world stage,” says Dr Atkinson. “In terms of product development, regulatory approvals, licensing and distribution, we’ve developed a good track record. Our first patented development product, Maxigesic tablets, is already approved and licensed in multiple European countries.”

“Raising new capital is really about taking this business to the next level and advancing our portfolio of innovative development products.”

Preliminary indications of interest may be made by contacting the Sole Lead Manager for the offer, First NZ Capital (0800 320 200) or an authorised financial advisor. No indications of interest will involve an obligation or commitment of any kind.

No money is currently being sought, and shares of AFT cannot currently be applied for or acquired under any offer or intended offer. If an initial public offer is made, it will be made in accordance with the Financial Markets Conduct Act 2013.

Q + A

Where is AFT based?

We are headquartered in Takapuna, Auckland. We also have offices in Sydney, Singapore and Kuala Lumpur.

What is the current ownership of the company?

Atkinson family interests own approximately 87% of the company. Specialty US healthcare investment company, CRG, increased its shareholding to 9% earlier this year. Milford Asset Management holds approximately 3% of the company acquired in 2014. The remaining shares in the company are held primarily by AFT board members and specialist overseas individual pharma investors.

Who is on the board of directors?

The chair of the AFT board is David Flacks. Also on the board are experienced pharma professionals, Nate Hukill and William Burns, both based in US, local directors Dr Doug Wilson and Jon Lamb, and founders Dr Hartley and Marree Atkinson.

What products does AFT sell/license?

A range of pharmaceutical products used in both residential and clinical settings including well known brands such as Maxigesic, Crystaderm, Zostrix, Coco-Scalp, Maxiclear Hayfever & Sinus, Maxiclear Cold & Nasal, Loraclear, Histaclear, Levoclear, Paracetamol OsteoTab, Ferro-F Tab and Ferro-Tab.

AFT has a number of innovative products that it has developed, or is developing, to sell directly in its home markets, or license to other companies around the world. It also has a medical device R&D programme.

Why is this IPO being considered?

While AFT has a strong established business in Australia and New Zealand, AFT also has a portfolio of innovative products that require investment to accelerate completion of their clinical development and introduction into markets around the world. Funds raised will be mainly used for this purpose, with some additional funds required for working capital and additional staff costs such as increasing AFT’s business development team and sales force in Australia.

ENDS

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Dairy NZ: ‘More Milk From Fewer Cows’ Trend Continues In A Record Year
Vodafone says it has 10,000 customers using its Wi-Fi Calling service. It took less than three months to reach that milestone; the service began operating in September... More>>

Statistics: Consents Remain At Record Levels
There were 47,715 new homes consented in the year ended October 2021, up 26 percent compared with the year ended October 2020, Stats NZ said today. "The year ended October 2021 marks another record for the annual number of new homes consented,” construction statistics manager Michael Heslop said... More>>



Foodstuffs: New World & Four Square Trial NZ’s First Grocery Delivery Offer With Uber Eats

New World & Four Square have partnered with Uber Eats to unlock the first grocery offering available on the platform in Aotearoa. For New World and Four Square it’s yet another way to put New Zealanders first, particularly with those inevitable last-minute grocery needs... More>>


Canterbury Museum: New Research - Bald Haast's Eagle Feasted On Moa Guts

New Zealand’s extinct Haast’s Eagle (Hieraaetus moorei), the largest known eagle, gulped down viscera like a vulture and may even have been bald, new research suggests... More>>

ABC Business Sales: Demand High For Covid-proof Businesses
Despite the continuing challenges facing businesses in this Covid environment, right now there are more buyers looking for a small-medium sized business than there are sellers in the market... More>>


PriceSpy: Producer Prices Increase
New Black Friday and Covid-19 Report* released by PriceSpy says people’s fear of stepping inside physical shops during big sales events like Black Friday has risen since last year; Kiwis are still planning to shop, but more than ever will do it online this year... More>>

NZ Skeptics Society: Announce Their 2021 Awards, And Dr Simon Thornley Wins The Bent Spoon

Every year the New Zealand Skeptics presents its awards to people and organisations who have impressed us or dismayed us, and this year it’s been hard to pick our winners because there have been so many choices!.. More>>